Haematologica最新文献

{"title":"Overuse of thrombopoietin receptor agonists driven by suboptimal response is associated with myelofibrosis in pediatric immune thrombocytopenia.","authors":"Jingyao Ma, Zhenping Chen, Xiaoling Cheng, Yu Hu, Jin Jiang, Jie Ma, Hongyun Lian, Liqiang Zhang, Xinyue Ma, Xi Lin, Shuyue Dong, Chuo Li, Wanru Yao, Shasha Zhao, Yunyun Wei, Runhui Wu","doi":"10.3324/haematol.2026.300651","DOIUrl":"https://doi.org/10.3324/haematol.2026.300651","url":null,"abstract":"<p><p>Not available.</p>","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":" ","pages":""},"PeriodicalIF":7.9,"publicationDate":"2026-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147837343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The development and preliminary validation of the CTCL-PRO-20: a novel quality of life survey for patients with cutaneous T-cell lymphoma.","authors":"Neha Akkad, Donna B Jeffe, Anastasia Krause, Noor Al-Hammadi, Marcus Watkins, Amy Musiek, Neha Mehta-Shah","doi":"10.3324/haematol.2025.300426","DOIUrl":"https://doi.org/10.3324/haematol.2025.300426","url":null,"abstract":"<p><p>Cutaneous T-cell lymphoma (CTCL) is a rare disease with a high symptom burden, negatively impacting patients' quality of life (QoL). There is no agreed-upon CTCL-specific metric to measure QoL in CTCL. Thus, we created a novel questionnaire to fill this gap. Eighty CTCLpatients participated in this cross-sectional survey study. An iterative process of principal components analysis (PCA) yielded a 5-component solution with 20 items; this patient-reported outcomes (PRO) questionnaire, the CTCL-PRO-20, had high internal-consistency reliability (Cronbach's α=0.93). Components measured self-consciousness (α =.94), treatment burden (α=.92), lack of CTCL resources (α=.74), sleep/fatigue (α=.87), and skin concerns (α=.88). High Pearson correlations were observed between the CTCL-PRO-20 and QoL measures more relevant to patients' experiences (e.g., MF/SS-CTCL QoL and Skindex-29); lower correlations were observed with the generic-QoL (SF-36) and single-focused (e.g., sleep-disturbance) measures. Patients with stable/no active disease (vs. progressive disease) reported significantly lower treatment-burden scores (better QoL). Patients who received systemic and topical treatments (vs. no treatment) reported significantly higher CTCL-PRO-20 scores (poorer QoL). This single-center study provides preliminary evidence of construct and convergent validity of the CTCL-PRO-20 and its components, warranting further validation in a well-powered study to examine its sensitivity to change after treatment intervention.</p>","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":" ","pages":""},"PeriodicalIF":7.9,"publicationDate":"2026-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147837412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Breaking barriers in rare disease research: a pilot trial of thromboprophylaxis with apixaban <i>versus</i> aspirin in JAK2-Positive myeloproliferative neoplasms.","authors":"Miriam Kimpton, Sonia Cerquozzi, Dominique Toupin, Jean-Christophe Ianotto, Pierre Villleneuve, Deborah M Siegal, Marc Carrier, Aurélien Delluc","doi":"10.3324/haematol.2026.301040","DOIUrl":"https://doi.org/10.3324/haematol.2026.301040","url":null,"abstract":"<p><p>Not available.</p>","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":" ","pages":""},"PeriodicalIF":7.9,"publicationDate":"2026-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147837250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Venetoclax and gilteritinib combination for <i>FLT3</i>-mutated relapsed/refractory acute myeloid leukemia: a real-world single-center experience.","authors":"Francesca Crupi, Gaia Ciolli, Matteo Piccini, Barbara Scappini, Laura Fasano, Elisa Quinti, Andrea Pasquini, Jessica Caroprese, Giacomo Gianfaldoni, Giovanna Motta, Raffaella Santi, Chiara Maccari, Paola Guglielmelli, Alessandro M Vannucchi, Francesco Mannelli","doi":"10.3324/haematol.2026.300692","DOIUrl":"https://doi.org/10.3324/haematol.2026.300692","url":null,"abstract":"","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":" ","pages":""},"PeriodicalIF":7.9,"publicationDate":"2026-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147837420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prothrombotic genetic variants and cancer-associated venous thromboembolism: defining thrombotic risk across tumor types.","authors":"Hannah Stevens, William W H Ho, Manika Singh, Rodrigo Canovas, Ruidong Xiang, Huyen Tran, Fumihiko Takeuchi, Karlheinz Peter, James D McFadyen","doi":"10.3324/haematol.2026.300579","DOIUrl":"https://doi.org/10.3324/haematol.2026.300579","url":null,"abstract":"<p><p>Cancer-associated venous thromboembolism (CAT) is a major cause of mortality in cancer patients. Prothrombotic genetic variants increase venous thromboembolism risk in the general population, but contribution to CAT remains unclear, particularly within different tumor types. We sought to determine whether the presence of thrombophilic variants influence relative and absolute CAT risk, and may be utilised in thromboprophylaxis decision-making. We evaluated 398,053 UK Biobank participants, of whom 42,122 developed cancer. A panel of seven thrombophilic variants (ABO, FGG, FXI, FVL, PTM, SLC44A2 and TSPAN15) were evaluated using multistate models, and 2-year absolute risk was estimated using Aalen- Johansen methods. We report hazard ratios (HRs) adjusting for age, sex, and body mass index. CAT incidence was 7.82% versus 2.08% in non-cancer participants. In the non-cancer population, all seven variants were associated with a higher risk of VTE. In patients with cancer, FVL conferred the highest risk (HR 1.81 for one risk allele; HR 5.75 for two risk alleles), followed by SLC44A2 (HR 1.51 for one risk allele, 1.53 for two risk alleles). Genetic effects were greatest in high-risk cancers, including pancreatic and lung cancers. For FVL heterozygotes, 2-year absolute VTE risk approximately doubled in several malignancies, including 5.17% to 9.26% in colorectal cancer and from 4.16% to 10.59% in lymphoma. In conclusion, thrombophilic variants, particularly FVL and SLC44A2, significantly increase the relative risk of CAT, with the largest effects in high-risk cancers. FVL has a marked impact on absolute CAT risk. Integrating genetic variants with clinical predictors can improve personalized thromboprophylaxis strategies.</p>","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":" ","pages":""},"PeriodicalIF":7.9,"publicationDate":"2026-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147837310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SWI/SNF alterations define a subgroup with poorer outcome among patients with aggressive forms of adult T-cell leukemia/lymphoma.","authors":"Romain Loyaux, Samy Chraibi, Maïa Pesic, Lucile Debus, Valérie Suez-Panama, Pascal Fuseau, Quentin Hurlot, Alina Danu, Véronique Vergé, Jean-Come Meniane, David Ghez, Christophe Marzac","doi":"10.3324/haematol.2026.300706","DOIUrl":"https://doi.org/10.3324/haematol.2026.300706","url":null,"abstract":"<p><p>Not available.</p>","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":" ","pages":""},"PeriodicalIF":7.9,"publicationDate":"2026-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147837363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Marked survival gains in patients ≤ 65 years with advanced-stage mantle cell lymphoma: a pooled analysis of six randomized phase III trials, 1996-2020.","authors":"Linmiao Jiang, Marco Ladetto, Olivier Hermine, Johanna C Kluin-Nelemans, Jan Walewski, Jeanette Doorduijn, Vibeke Vergote, Eva Giné, Mats Jerkeman, Martin Hutchings, Marek Trneny, Ulrich Mey, Jon Riise, Ofer Shpilberg, Maria Gomes Da Silva, Vincent Ribrag, Christian Schmidt, Wolfram Klapper, Michael Unterhalt, Martin Dreyling, Eva Hoster","doi":"10.3324/haematol.2025.288929","DOIUrl":"10.3324/haematol.2025.288929","url":null,"abstract":"<p><p>Mantle cell lymphoma (MCL) remains a challenging and generally incurable disease. We aimed to evaluate survival trends in advanced-stage MCL over the past three decades, focusing on the impact of evolving first-line therapies. We pooled six randomized phase III trials of treatment-naïve, advanced-stage MCL patients enrolled between 1996 and 2020. Patients were grouped into four eras by enrollment period. Failure-free survival (FFS) and overall survival (OS) were compared across eras using Kaplan-Meier methods and Cox regression adjusted for the Mantle Cell Lymphoma International Prognostic Index (MIPI) and treatment. Dynamic survival trends were analyzed using penalized splines. Among 2,541 MCL patients, survival outcomes have improved steadily since 1996. In younger and transplant-eligible patients (≤ 65 years), there was a strong increase in median OS from 4.9 years (5-year OS: 49%) in the period 1996-2000 to 13.8 years (73%) in 2004-2014 and was not reached (84%) in 2016-2020. In older and transplant-ineligible patients, median OS improved from 3.8 to 4.8 years (5-year OS: 40-49%) between 1996 and 2014. Dynamic trends revealed a sharp decline in treatment failure and mortality risk between 2000 and 2005, followed by sustained improvements. Patients receiving the same treatment regimens had comparable FFS and OS across eras. Adjusting for treatment eliminated most survival trends, underscoring the impact of rituximab, ASCT, high-dose cytarabine, and ibrutinib on survival improvements. In conclusion, OS in MCL has substantially improved over the past three decades, especially in younger patients, driven largely by improvements in first-line treatment. In older patients, despite significantly improved OS in recent decades, there remains an urgent need for further improvements.</p>","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":" ","pages":"1694-1704"},"PeriodicalIF":7.9,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13136794/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145400662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Defying age: myth or reality?","authors":"Mary Eapen","doi":"10.3324/haematol.2025.289061","DOIUrl":"10.3324/haematol.2025.289061","url":null,"abstract":"","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":" ","pages":"1520-1522"},"PeriodicalIF":7.9,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13136824/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145299861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical decisions in clonal hematopoiesis: a contemporary review for clinicians.","authors":"Robert J Vanner, Andy G X Zeng, Raymond H Kim, Steven Chan, Aniket Bankar","doi":"10.3324/haematol.2025.287422","DOIUrl":"10.3324/haematol.2025.287422","url":null,"abstract":"<p><p>Clonal hematopoiesis (CH) has emerged as a critical mediator of age-associated diseases, with far-reaching implications for hematologic malignancies, cardiovascular diseases, cancer therapy, autoimmune disorders, and other health conditions. This review synthesizes the current evidence supporting the integration of CH testing and monitoring into clinical practice, with a focus on translating scientific discoveries into actionable diagnostic and therapeutic strategies. We present a systematic framework for establishing and operating a dedicated CH program, drawing on institutional experience and evolving best practices. Our analysis encompasses risk stratification approaches, surveillance protocols, and intervention timing for various CH-associated conditions. Special attention is given to the challenges and opportunities in implementing CH screening within existing clinical workflows, including considerations regarding genetic counseling, interdisciplinary coordination, and patient education. By providing practical insights and evidence-based recommendations, this review aims to serve as a roadmap for healthcare institutions looking to develop comprehensive CH management programs that bridge the gap between molecular discoveries and clinical care delivery.</p>","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":" ","pages":"1584-1609"},"PeriodicalIF":7.9,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13136818/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146124714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Introduction to the Review Series. Clonal hematopoiesis review series - from biology to clinical management.","authors":"Anastasija A Piric, Aaron D Schimmer","doi":"10.3324/haematol.2025.288295","DOIUrl":"10.3324/haematol.2025.288295","url":null,"abstract":"","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":"111 5","pages":"1532-1535"},"PeriodicalIF":7.9,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13136806/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147814257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}